-
Uncategorized2 months ago
FDA rejects Replimune’s melanoma prospect for second time
The second time is not the charm for Replimune’s melanoma candidate RP1. After spurning the immunotherapy last July, the FDA has now rejected the biotech’s resubmitted...
-
Uncategorized2 months agoSTAT+: GSK says goodbye to leucovorin (again)
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Buyer beware: If you are an avid consumer...
-
Uncategorized2 months agoThis week in Drug Discovery (6 – 10 April)
News round-up for 6 – 10 April by Bruno Quinney, Content Team at DDW. This week, researchers have discovered how genetic mutations cause a previously unknown recessive condition....
-
Uncategorized2 months ago
Novo’s double departures: As GLP-1 luminary retires, an obesity leader goes to Boehringer Ingelheim
Novo's double departures: As GLP-1 luminary retires, an obesity leader goes to Boehringer Ingelheim
-
Uncategorized2 months agoWomen have awaited a revolution in menopause. It hasn’t arrived.
Persistent barriers are still hindering drug development for a host of menopause symptoms. Read More
-
Uncategorized2 months agoOpinion: What public health can learn from the MAHA movement
I didn’t expect to find myself face to face with leaders and activists from the “Make America Healthy Again” movement in respectful dialogue, or to consider...
-
Uncategorized2 months ago
GSK CEO’s ‘scientific courage’ propels plans for medley of phase 3 trials for Hansoh-partnered ADC
When Fierce last caught up with GSK’s head of oncology R&D back in November, we were told to “stay tuned” for the pharma to publish its...
-
Uncategorized2 months agoCancer Drug Shortfalls Tied to How BET Inhibitors Hit BRD2 and BRD4 Differently
For more than a decade, BET inhibitors have been touted as one of cancer therapy’s most promising drug classes. The logic was straightforward: many tumors rely...
-
Uncategorized2 months agoSTAT+: Top health officials highlight efforts to make medical records more portable
Zac Jiwa, a federal Medicare official, delivered a eulogy of sorts at a Thursday Medicare event highlighting the successes of the Health Tech Ecosystem initiative. The...
-
Uncategorized2 months ago
BBB Access Route via Proteomic Vascular Mapping
A limiting feature of many neurological therapies is the ability of molecules to cross the blood-brain barrier (BBB) from the circulatory system. Since the BBB prevents...
